The onset of neurological disorders, such as autism, in childhood is not associated with the use of paracetamol during pregnancy or infancy. This is the conclusion of a comprehensive meta-analysis that comprises 43 scientific studies and was published in The Lancet Obstetrics, Gynaecology & Women's Health, one of the most authoritative international journals in the field of maternal and infant medicine. The study is the outcome of a worldwide, multidisciplinary partnership that included experts in epidemiology, obstetrics, and public health. Professor Maria Elena Flacco of the University of Ferrara and Professor Francesco D'Antonio of the University "G. d'Annunzio" of Chieti coordinated the event. "The data analysis does not reveal any evidence that the risk of autism spectrum disorders, ADHD, or intellectual disability in girls and boys is increased by the consumption of paracetamol during pregnancy", the researchers clarify. "These findings are significant because they give a more solid foundation for clinical decisions and accurate scientific communication directed at both healthcare professionals and the general public", they continued. Some statements from the United States in September 2025 indicated a potential correlation between the use of paracetamol during pregnancy and an elevated risk of cognitive developmental disorders in children. These statements drew extensive media attention, causing widespread worry among the general public. The study's authors warn that "any medication must be used appropriately, according to clinical indications". However, according to the present scientific research, "there is no evidence to justify specific alarmism regarding the use of paracetamol in relation to autism or other neurological disorders".